Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Interleukin-12 (IL-12) production pathway is a fundamental immunological process that coordinates the transition from innate to adaptive immunity by promoting the differentiation of T-helper 1 (Th1) cells. This pathway is initiated in antigen-presenting cells, such as macrophages and dendritic cells, upon the recognition of pathogen-associated molecular patterns (PAMPs) by receptors like Toll-like receptors (TLRs) (Trinchieri, 2003). The resulting production of IL-12, a heterodimeric cytokine consisting of p35 and p40 subunits, triggers the activation of the JAK-STAT signaling cascade in T cells and natural killer (NK) cells, leading to the secretion of interferon-gamma (IFN-γ) (Watford et al., 2004). Overactivation of the IL-12 production pathway is strongly associated with the pathogenesis of chronic inflammatory conditions, including psoriasis, Crohn's disease, and ulcerative colitis (Teng et al., 2015). Therapeutic strategies targeting this pathway include monoclonal antibodies like ustekinumab, which neutralizes the shared p40 subunit of IL-12 and IL-23, and small molecules like apremilast that modulate upstream intracellular signaling to reduce cytokine synthesis (DrugBank, 2024). While effective in treating autoimmune diseases, inhibiting this pathway can increase patient susceptibility to intracellular infections, such as tuberculosis and salmonellosis, due to the compromised Th1-mediated immune response (StatPearls, 2023). Additionally, because IL-12 plays a role in tumor surveillance, long-term suppression of this pathway raises theoretical concerns regarding the development of malignancies.
Drugs targeting this pathway primarily act by neutralizing the IL-12 cytokine (specifically the p40 subunit) to prevent its interaction with the IL-12 receptor, or by inhibiting upstream signaling molecules like PDE4 to decrease the transcription and secretion of IL-12 from immune cells.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Interleukin-12 (IL-12) production pathway (IL-12 pathway).